Blood test may spot lupus kidney damage early, reducing need for biopsies
NCT ID NCT07505576
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether measuring anti-alpha-actinin antibodies in the blood can help identify active lupus nephritis (kidney inflammation) in people with lupus. Researchers will compare antibody levels with findings from standard kidney biopsies in 96 adults. If the blood test works well, it could become a simpler, less invasive way to monitor kidney disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
serum anti-alpha-actinin antibodies (diagnostic test)
What this could lead to
If successful, this blood test could help doctors detect active lupus nephritis earlier and more easily, potentially reducing the need for invasive kidney biopsies.
What could go wrong
This is an early, observational study with only 96 participants. The antibody test may not prove accurate enough to replace biopsies, and results may not apply to all lupus patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••